^
    Back
    Association details:
    Biomarker:BRAF mutation + NF1 mutation
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Rep
    Title:

    Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

    Published date:
    04/05/2022
    Excerpt:
    Concordantly, BRAF inhibitors that inhibit both monomeric and dimeric BRAF synergize with MEK inhibition to significantly reduce cell viability in vitro and tumor growth in vivo in BRAF non-p.V600 mutant melanomas with co-occurring NF1 loss-of-function mutations. Our data suggest that patients harboring BRAF non-p.V600 mutant melanomas may benefit from current FDA-approved BRAF/MEK inhibitor combination therapy currently reserved for BRAF p.V600 mutant patients.
    DOI:
    10.1016/j.celrep.2022.110634